此乃要件 請即處理 閣下如對本通函任何方面或應採取之行動有任何疑問，應諮詢 閣下之股票經紀或其他註冊證券商、 銀行經理、律師、專業會計師或其他專業顧問。 閣下如已售出或轉讓 所 有 名 下 中 國 生 命 集 團 有 限 公 司（「本 公 司」）之 股 份，應 立 即 將 本 通 函 送 交 買 主 或承讓人，或經手買賣或轉讓之銀行、股票經紀或其他代理商，以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本通函全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：8296） (1)購回及發行股份的一般授權； (2)重選退任董事； 及 (3)股東週年大會通告 本通函連同本公司二零二四年年報一併寄發，而二零二四年年報載有董事會報告、獨立核數師報告 及本公司與其附屬公司截至二零二四年十二月三十一日止年度之經審核財務報表。 本 公 司 謹 訂 於 二 零 二 五 年 六 月 二 十 五 日（星 期 三）上 午 十 一 時 ...

(Incorporated in the Cayman Islands with limited liability) （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） (Stock Code: 8296) （股份代號：8296） NOTIFICATION LETTER 通知信函 If you wish to receive the printed version of the 2024 ESG Report, you may send your request in writing to the registered office of the Company in Hong Kong at 18/F, Ovest, 77 Wing Lok Street, Sheung Wan, Hong Kong. By order of the Board Sino-Life Group Limited XU Jianchun Chairman and Executive Director * Please affix appropriate postage stamp when posting. 各位股 ...

資本服務 科技 科技 創造價值 2024 ESG Report 環境、社會及管治報告 Environmental, Social and Governance Report 環境、社會及管治報告 ABOUT THIS REPORT Sino-Life Group Limited (the "Company"), together with its subsidiaries (the "Group"), is pleased to present this Environmental, Social and Governance Report (the "Report") to provide an overview of the Group's management of significant issues affecting the operation, including environmental, social and governance ("ESG") issues. This Report is prepared by the Group with the professional assis ...

Economic Growth and Market Outlook - In 2024, China's GDP growth target was achieved at 5%, despite a turbulent global economic environment and domestic structural challenges [20]. - China's GDP growth for 2024 is projected at 5.0%, meeting the government's target despite challenges such as weak domestic consumption and a property downturn [45]. - In Q4 2024, GDP growth accelerated to 5.4% year-on-year, supported by stimulus measures aimed at boosting domestic demand [45]. - The Chinese government is expected to maintain stimulus measures and fiscal support to bolster sustainable domestic demand, contributing to a moderate recovery trajectory for the economy [32]. - China's GDP is expected to expand at around a 5% target in 2025, reflecting structural challenges such as a persistent property downturn and subdued domestic consumption [157]. Funeral and Cremation Services Market - The funeral and cremation services market in China is projected to grow at a compound annual growth rate of over 3% from 2024 to 2029, with approximately 4,605 funeral service institutions operating by 2023 [21]. - The funeral and related services sector is expected to grow at a modest annual rate of 3% to 4% in 2025, driven by an aging population and sustained demand for innovative services [33]. - Cremation rates increased from 55.7% in 2020 to 58.8% in 2021, indicating a shift in consumer preferences towards cremation over traditional burials [51]. - The number of funeral service institutions rose from approximately 4,474 in 2022 to 4,605 in 2023, reflecting a mature yet competitive market [51]. - The medium-term growth outlook for the funeral and related services sector is expected to be modest, with an annual expansion rate around 3% to 4% [161]. Biotechnology Sector Insights - The emerging biotechnology segment shows significant long-term potential, driven by government initiatives like "Healthy China 2030" and substantial investments in biomedicine and precision oncology [22]. - The biotechnology sector will continue to see government initiatives driving innovation, particularly in biomedicine, regenerative medicine, and precision oncology [34]. - The biotechnology sector in China is experiencing a cautious funding environment in 2024, which may moderate growth compared to the previous year [52]. - Significant investments in research and development are shifting the focus from generics to novel drug development, supported by government initiatives [52]. - The application of digital technologies such as AI, big data, and blockchain is expected to reduce healthcare service costs and promote sustainable development in the biotechnology industry [164]. Financial Performance and Revenue - The loss attributable to the owners of the Company for 2024 was approximately RMB8,699,000, compared to RMB7,173,000 for the prior year, indicating a decline in profitability [29]. - The Group's revenue from funeral, cremation, and cemetery services increased by approximately 1.8% year-on-year, from approximately RMB65,838,000 in the Prior Year to approximately RMB67,035,000 in the Year [62]. - Revenue from funeral services segment in China was approximately RMB70,443,000, reflecting a year-over-year increase from approximately RMB69,501,000 [72]. - The overall profit margin for the Group decreased to 4.9% in 2024 from 6.5% in 2023 [71]. - Other income and net gains decreased by approximately 14.3% to RMB 2,204,000 from RMB 2,571,000 in the prior year [81]. Strategic Initiatives and Operational Efficiency - The Group plans to enhance operational efficiency in its traditional funeral services business by optimizing cost structures and streamlining service delivery in 2025 [38]. - The Group aims to leverage technological integration to enhance customer experience and drive cost efficiencies in an increasingly competitive market [38]. - The Company will focus on operational efficiency and strategic partnerships to adapt to macroeconomic signals and consumer confidence [56]. - The Group's strategic focus includes operational efficiency and monitoring macroeconomic signals to adjust business strategies accordingly [58]. - The Group's strategic initiatives focus on enhancing market presence and optimizing costs in response to changing consumer preferences and economic conditions [82]. Investment Strategy and Portfolio Management - The Group's investments in biotechnology, particularly through its subsidiary Zhongke Zhenhui (Guangdong) Medical Technology Company Limited, will remain a cornerstone of its long-term strategy [34]. - The Group aims to broaden its income sources and maximize returns by investing in various equity securities, ETFs, debt instruments, and derivative instruments [115]. - The Group's investment strategy includes maintaining a balanced portfolio to mitigate risks and enhance returns for shareholders [120]. - The Group's investment portfolio constituted only 3.1% of the total assets as of December 31, 2024, with the largest single security exposure being 3.0% [120]. - The Group's liquidity position remains strong, with sufficient resources to meet commitments and working capital requirements, despite uncertainties in economic conditions [106]. Corporate Governance and Compliance - The Board held only three regular meetings during the year, failing to meet the requirement of at least four meetings annually [177]. - The Board comprises a balanced composition with 50% independent non-executive Directors, exceeding GEM Listing Rules requirements [200]. - The company has implemented mechanisms to ensure independent views are available to the Board, reviewed annually for effectiveness [199]. - All Directors confirmed compliance with the securities trading code throughout the year [183]. - There were no known non-compliance incidents during the year [184].

Financial Performance - For the fiscal year ending December 31, 2024, the company reported total revenue of RMB 74,943,000, an increase from RMB 72,570,000 in the previous year, representing a growth of approximately 3.25%[7] - The gross profit for the same period was RMB 32,283,000, a decrease from RMB 33,481,000, indicating a decline of about 3.57%[7] - The company experienced a pre-tax loss of RMB 7,454,000, slightly improved from a loss of RMB 7,943,000 in the prior year, reflecting a reduction in losses of approximately 6.15%[7] - The net loss for the year was RMB 10,402,000, compared to a net loss of RMB 10,086,000 in the previous year, showing an increase in losses of about 3.13%[7] - Total comprehensive income for the year was RMB 757,000, compared to RMB 5,801,000 in the previous year, indicating a significant decline[8] - The company reported a basic loss per share of RMB (9.48) cents, compared to RMB (8.99) cents in the previous year[8] Revenue Breakdown - The group reported total revenue of RMB 74,943 thousand for the year ended December 31, 2024, with RMB 70,443 thousand from funeral services and RMB 4,500 thousand from biotechnology and other businesses[30] - For the year ended December 31, 2023, total revenue was RMB 72,570 thousand, with RMB 69,501 thousand from funeral services and RMB 3,069 thousand from biotechnology[31] - The revenue from funeral services increased from RMB 65,838 thousand in 2023 to RMB 67,035 thousand in 2024, representing a growth of approximately 1.8%[30][31] - Revenue from biotechnology and other businesses reached RMB 4,500,000 in fiscal year 2024, compared to RMB 3,069,000 in the previous year, marking a significant increase[51] Expenses and Liabilities - Administrative expenses decreased to RMB 36,336,000 from RMB 41,044,000, representing a reduction of approximately 11.4%[7] - The company incurred a fair value loss on investment properties of RMB 748,000, which is an improvement from a loss of RMB 1,081,000 in the previous year[7] - The expected credit loss on trade and other receivables was RMB 4,150,000, a significant increase from a reversal of RMB 2,841,000 in the previous year[7] - Total liabilities decreased to RMB 133,611,000 from RMB 145,882,000 year-over-year[12] Assets and Equity - Non-current assets totaled RMB 54,248,000, down from RMB 58,619,000 year-over-year[9] - Current assets decreased to RMB 196,378,000 from RMB 213,088,000 in the previous year[9] - The company's equity attributable to owners increased to RMB 123,452,000 from RMB 123,718,000[12] - Cash and cash equivalents were reported at RMB 109,256,000, down from RMB 125,019,000[9] Strategic Focus and Future Plans - The company plans to focus on market expansion and new product development in the upcoming fiscal year[6] - The company aims to diversify its development and achieve high-quality economic growth to effectively address geopolitical risks and market complexities[98] - The company emphasizes the importance of operational efficiency, technological innovation, and strategic partnerships to adapt to market opportunities[97] Market and Economic Outlook - China's GDP growth rate for 2024 is projected to be around 5.0%, despite facing structural challenges such as weak domestic consumption and a sluggish real estate market[40] - The funeral and related services industry is expected to maintain stable growth, with a compound annual growth rate exceeding 3% from 2024 to 2029[41] - The biotechnology sector in China continues to show strong innovation capabilities, supported by regulatory reforms and increased government funding[43] Compliance and Governance - The board of directors confirmed the accuracy and completeness of the financial information presented in the report[5] - The company did not declare or recommend any dividends for the years ending December 31, 2023, and 2024[34] - The company has complied with relevant laws and regulations, with no significant violations reported during the year[110] Investment and Financial Management - The company made total investments of approximately RMB 894,796,000 during the year, including various financial instruments[71] - The fair value of the investment portfolio as of December 31, 2024, was approximately RMB 7,716,000, down from RMB 14,532,000 in 2023[69] - The group continues to adopt a conservative treasury policy, primarily conducting its ongoing business transactions in RMB and HKD[76]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因本公佈全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失 承 擔 任 何 責 任。 （股份代號：8296） （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） 董事會會議通告 中 國 生 命 集 團 有 限 公 司（「本公司」）之 董 事（「董 事」）會（「董事會」）謹 此 宣 布， 董 事 會 會 議 將 於 二 零 二 五 年 三 月 二 十 七 日（星 期 四）舉 行，以 便 處 理 下 列 事 項： 承董事會命 中國生命集團有限公司 主席兼執行董事 本公告的資料乃遵照香港聯合交易所有限公司GEM證 券 上 市 規 則 而 刊 載， 旨 在 提 供 有 關 本 公 司 的 資 料；本 公 司 的 董 事 願 就 本 公 告 的 資 料 共 同 及 個 別地承擔全部責任。各董事在作出一切合理查詢後，確認就其所知及所信， 本 公 告 所 載 資 料 在 各 重 要 方 面 均 屬 準 確 完 備，沒 有 誤 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損 失 承 擔 任 何 責 任。 本 公 告 僅 供 參 考，並 不 構 成 收 購、購 買 或 認 購 本 公 司 任 何 證 券 之 邀 請 或 要 約。 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：8296） 許建春 香 港，二 零 二 五 年 一 月 六 日 收購廣東因微約19.46%股 權 涉及根據特別授權發行可換股債券 之須予披露及關連交易失效 茲提述(i)本公司日期為二零二四年七月二十九日及二零二四年十月九日 之 公 告；及(ii)本 公 司 日 期 為 二 零 二 四 年 九 月 十 六 日 之 通 函（「通 函」），內 容有關收購廣東因微約19.46%股權涉及根據特別授權發行可換股債券之 須 予 披 露 及 關 連 交 易。除 另 有 指 明 外，本 公 告 所 用 詞 彙 與 通 函 所 界 定 者 具 有 相 同 涵 義 ...

Dividend Policy - The board does not recommend the payment of any interim dividend for the current period, consistent with previous periods[1] Financial Results - The announcement pertains to the interim results for the six months ending June 30, 2024[1] - The announcement was made on August 30, 2024, by the board of directors of China Life Group Limited[2]

Financial Performance - For the six months ended June 30, 2024, the group reported revenue of RMB 34,383,000, a decrease of 15.7% compared to RMB 40,831,000 for the same period in 2023[2] - The gross profit for the period was RMB 11,971,000, down 29.4% from RMB 16,996,000 in the previous year[2] - The operating loss increased to RMB 6,745,000, compared to an operating loss of RMB 2,241,000 in the prior period, reflecting a significant deterioration in performance[2] - The net loss for the period was RMB 8,909,000, which is a 95.2% increase from the net loss of RMB 4,561,000 in the same period last year[3] - Basic loss per share was RMB 0.96, compared to RMB 0.51 in the previous year, indicating a worsening financial position[3] - The total comprehensive loss for the period was RMB 8,374,000, significantly higher than RMB 1,915,000 in the prior year, highlighting increased financial challenges[3] - The group reported a pre-tax comprehensive loss of RMB 7,673 thousand for the six months ended June 30, 2024, compared to a loss of RMB 3,184 thousand in the same period of 2023[22] - The company reported a loss attributable to owners of approximately RMB 8,665,000, compared to RMB 3,791,000 in the previous period, with a loss per share of approximately RMB 0.96[81] Revenue Breakdown - The group's revenue from funeral services and cremation services for the six months ended June 30, 2024, was RMB 33,007,000, a decrease of 8.2% compared to RMB 35,957,000 for the same period in 2023[17] - Revenue from funeral arrangements and related consulting services was RMB 1,376,000, down 11.5% from RMB 1,554,000 in the previous year[17] - The company's total revenue for the six months ended June 30, 2024, was RMB 222,510 thousand, compared to RMB 290 thousand for the same period in 2023[8] - Revenue from the Chinese market was approximately RMB 33,007,000, down about 8.2% from RMB 35,957,000 in the previous period[76] - Revenue from Taiwan was approximately RMB 962,000, relatively stable compared to RMB 967,000 in the previous period[77] - Revenue from Hong Kong significantly decreased from approximately RMB 3,586,000 in the previous period to about RMB 414,000 in the current period[77] - The company ceased sales activities in Vietnam due to a significant decline in demand for burial plots, resulting in zero revenue contribution from this market[78] Assets and Liabilities - Total assets decreased to RMB 208,064,000 from RMB 213,088,000, reflecting a decline in the company's asset base[5] - Cash and bank balances were reported at RMB 118,770,000, down from RMB 125,019,000, indicating a reduction in liquidity[5] - The company's equity attributable to owners decreased to RMB 87,489,000 from RMB 81,947,000, showing a slight improvement in equity position despite losses[5] - The fair value of financial assets measured at fair value through profit or loss was RMB 45,336,000 as of June 30, 2024, down from RMB 48,495,000 as of December 31, 2023[45] - The total amount of prepayments, deposits, and other receivables increased to RMB 39,018,000 as of June 30, 2024, compared to RMB 34,166,000 as of December 31, 2023[48] - Trade payables as of June 30, 2024, were RMB 1,470,000, a decrease from RMB 1,941,000 as of December 31, 2023[51] Cash Flow - The company reported a net cash outflow from operating activities of RMB (12,145) thousand for the six months ended June 30, 2024, compared to a net inflow of RMB 5,547 thousand for the same period in 2023[9] - The net cash inflow from investing activities was RMB 704 thousand for the six months ended June 30, 2024, down from RMB 4,135 thousand in the previous year[9] - The net cash inflow from financing activities was RMB 1,534 thousand for the six months ended June 30, 2024, compared to a net outflow of RMB (3,889) thousand in 2023[9] - The cash and cash equivalents decreased by RMB (9,907) thousand for the six months ended June 30, 2024, while it increased by RMB 5,793 thousand in the same period of 2023[9] Employee and Management Costs - Employee costs, including director remuneration, decreased to RMB 14,658 thousand from RMB 17,320 thousand year-on-year[35] - The short-term employee benefits for key management personnel for the six months ended June 30, 2024, totaled RMB 3,677,000, an increase from RMB 2,308,000 in the previous year[63] - The total amount payable to directors as of June 30, 2024, was RMB 5,333,000, compared to RMB 4,681,000 as of December 31, 2023, reflecting an increase of approximately 13.9%[67] Strategic Focus and Future Plans - The company aims to enhance its research capabilities and product offerings through the acquisition of Guangdong Yimicro, which specializes in biochip development and personalized medical consultation services[70] - The biotechnology sector is identified as a long-term strategic focus, with significant progress made in life sciences instrument sales since 2019[94] - The group plans to leverage opportunities in the biotechnology field, particularly in biomedicine and healthcare, as part of its investment strategy[94] - The company plans to propose a share consolidation, merging every ten shares of HKD 0.1 into one share of HKD 1.0, which will reduce the total number of shares from 10 billion to 1 billion[71] Governance and Compliance - The company's governance practices are based on the GEM Listing Rules, emphasizing high-quality board composition and transparency to shareholders[112] - An audit committee has been established, consisting of three independent non-executive directors, to oversee financial reporting and internal control systems[116] - The audit committee reviewed the unaudited condensed consolidated financial statements for the period and confirmed compliance with applicable accounting standards[116]

Financial Performance - The company reported a total revenue of RMB 34,383,000 for the six months ended June 30, 2024, compared to RMB 40,831,000 for the same period in 2023, representing a decrease of approximately 15.8%[2] - The gross profit for the period was RMB 11,971,000, down from RMB 16,996,000 in the previous year, indicating a decline of about 29.3%[2] - The net loss attributable to the owners of the company was RMB 8,665,000, compared to a loss of RMB 3,791,000 in the prior year, reflecting an increase in losses of approximately 128.5%[3] - The total comprehensive income for the period, after tax, was RMB 535,000, down from RMB 2,646,000 in the previous year[2] - The basic loss per share for the period was RMB 0.96, compared to RMB 0.51 in the same period last year, representing an increase of approximately 88.2%[3] - The group reported a segment operating profit of RMB 914 thousand for the six months ended June 30, 2024, compared to RMB 4,693 thousand for the same period in 2023, indicating a significant decrease of approximately 80%[21] - The company reported a loss attributable to owners of RMB 8,665,000, compared to a loss of RMB 3,791,000 in the previous period[79] Assets and Liabilities - The company's total assets as of June 30, 2024, were RMB 262,052,000, a slight decrease from RMB 271,707,000 as of December 31, 2023[4] - Current liabilities amounted to RMB 128,704,000, compared to RMB 131,569,000 at the end of 2023, showing a decrease of about 2.1%[4] - The company’s non-current assets totaled RMB 53,988,000, down from RMB 58,619,000 at the end of 2023, reflecting a decrease of about 7.8%[4] - The company’s equity attributable to owners was RMB 105,947,000, a decrease from RMB 108,533,000 at the end of 2023, indicating a decline of approximately 2.4%[5] - Total liabilities decreased from RMB 12,074,000 as of December 31, 2023, to RMB 11,866,000 as of June 30, 2024[44] Cash Flow - For the six months ended June 30, 2024, the net cash used in operating activities was RMB (12,145) thousand, compared to RMB 5,547 thousand for the same period in 2023[8] - The net cash generated from investing activities was RMB 704 thousand, a decrease from RMB 4,135 thousand in the previous year[8] - The net cash generated from financing activities was RMB 1,534 thousand, compared to a net cash used of RMB (3,889) thousand in the prior year[8] - As of June 30, 2024, cash and cash equivalents decreased by RMB (9,907) thousand, while the balance at the beginning of the period was RMB 125,019 thousand[8] Revenue Breakdown - Revenue from funeral services and cremation services for the six months ended June 30, 2024, was RMB 33,007,000, a decrease of 8.4% from RMB 35,957,000 in the same period of 2023[15] - Revenue from funeral arrangement and related consulting services was RMB 1,376,000, down 11.5% from RMB 1,554,000 in the previous year[15] - Revenue from funeral services in China was RMB 33,007 thousand for the six months ended June 30, 2024, down from RMB 35,957 thousand in the same period of 2023, representing a decline of approximately 5.4%[22][25] - Revenue from Taiwan for the six months ended June 30, 2024, was RMB 962 thousand, slightly down from RMB 967 thousand in the same period of 2023[25] - Revenue from Hong Kong significantly decreased from RMB 3,586,000 to RMB 414,000, primarily due to the absence of high-end biotechnology equipment sales[76] - Revenue contribution from Vietnam was zero, down from RMB 321,000 in the previous period, reflecting a strategic decision to cease sales activities in that market[77] Operational Highlights - The company is primarily engaged in investment holding and provides funeral and related services in China, Taiwan, and Hong Kong[9] - The group has two reportable segments: funeral services and stem cell & immune cell business, with the former including related services and the latter involving high-end biotechnology instruments[17] - The group’s internal reporting to executive directors is consistent with the way it manages its business by segmenting based on business type and region[16] Strategic Initiatives - The company aims to enhance its research capabilities and product offerings in the biotechnology sector through the acquisition of Guangdong Yimicro, which specializes in biochip development and personalized medical consultation services[69] - The company has established a specialized investment team to accelerate the development of its biotechnology business, focusing on areas such as biomedicine and life sciences instruments[72] - The company is committed to innovation-driven development and supporting emerging industries to navigate geopolitical risks and market complexities[93] - The company has identified strategic investments in biotechnology, biomedicine, and life sciences instruments as key areas for future growth[93] Shareholder Information - The total equity held by Mr. Xu in the company amounts to 364,601,984 shares, representing approximately 38.58% of the total issued shares[94] - The major shareholder, Hong Kong Gaoqi Biotechnology Co., holds 220,475,000 shares, accounting for approximately 23.33% of the total issued share capital[96] - The company issued a total of 60,000,000 new shares to six independent shareholders on June 14, 2024[51] Governance and Compliance - The board has confirmed compliance with the corporate governance code, with a noted absence of an independent non-executive director at the annual general meeting due to other business commitments[110] - The audit committee has been established and consists of three independent non-executive directors, ensuring compliance with GEM listing rules[114] - The audit committee reviewed the unaudited consolidated financial statements for the period and confirmed adherence to applicable accounting standards[114]